What FDA CBER regulates and how the center differs from CDER
FDA CBER is the Center for Biologics Evaluation and Research. It regulates vaccines, blood, tissues and cell and gene therapies, not every biologic.
What FDA CBER regulates and how it differs from CDER
FDA CBER is the Center for Biologics Evaluation and Research, which regulates biological products for human use (FDA, CBER overview). Those products include vaccines, blood and blood products, human tissues, and cell and gene therapies (FDA, CBER product jurisdiction).
CBER does not regulate every biologic. FDA's Center for Drug Evaluation and Research (CDER) handles specified therapeutic biological products, as explained in FDA's transfer notice.
What the Center for Biologics Evaluation and Research covers
FDA's CBER product jurisdiction page lists these product categories: allergenics, blood and blood products, cellular and gene therapies, tissues and tissue-based products, vaccines, live biotherapeutic products and xenotransplantation products. CBER also regulates some devices, including selected in vitro diagnostics and devices that manufacture a biologic at the point of care, and a small number of drug products related to blood banking or cellular therapies. The page identifies three product-review offices:
| Office | What it regulates |
|---|---|
| Office of Vaccines Research and Review (OVRR) | Generally vaccines against infectious diseases, allergenic products, and live biotherapeutic (probiotic) therapies |
| Office of Blood Research and Review (OBRR) | Blood and blood products for transfusion, blood-donor screening assays, retroviral diagnostic tests |
| Office of Therapeutic Products (OTP) | Cell, tissue and gene therapies, therapeutic vaccines for noninfectious diseases, plasma derivatives and their recombinant analogues |
FDA established the Office of Therapeutic Products by reorganizing the former Office of Tissues and Advanced Therapies (OTAT) (FDA announcement).
CBER vs CDER
On June 30, 2003, FDA transferred specified therapeutic biological products from CBER to CDER. The transfer covered monoclonal antibodies for in vivo use and therapeutic proteins such as cytokines and enzymes, except products specifically assigned to CBER, such as vaccines and blood products (FDA, transfer of therapeutic biological products).
Both centers regulate biologics. The distinction is not simply chemical drugs versus biological products, nor whether a product is "living." FDA's category lists guide jurisdiction checks. They are not product-specific assignment decisions.
How human tissues fit (21 CFR 1271)
FDA calls these HCT/Ps: human cells, tissues, and cellular and tissue-based products. Examples include bone, skin, corneas, heart valves and cord-blood hematopoietic stem/progenitor cells. CBER does not regulate vascularized human organ transplantation. FDA identifies HRSA oversight (FDA, tissue and tissue products).
Under 21 CFR 1271.10(a), an HCT/P is regulated solely under section 361 of the Public Health Service (PHS) Act and Part 1271 only if it meets all of the applicable criteria:
- it is minimally manipulated
- it is intended for homologous use only
- its manufacture does not combine the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, if that addition raises no new clinical safety concerns
- either it has no systemic effect and does not depend on the metabolic activity of living cells for its primary function, or, where one of those applies, it is for autologous use, allogeneic use in a first- or second-degree blood relative, or reproductive use
Minimal manipulation on its own is not enough. An HCT/P that fails these criteria, and is not covered by an exception in section 1271.15, is regulated as a drug, device and/or biological product under the Federal Food, Drug, and Cosmetic (FD&C) Act and/or section 351 of the PHS Act (21 CFR 1271.20). Check the section 1271.15 exceptions before drawing a conclusion for a specific tissue.
Tissue establishments also face registration, donor screening and testing, and good tissue practice requirements where they apply (FDA, tissue and tissue products). FDA states that accepting a registration and HCT/P listing is not a finding of compliance and does not mean the HCT/P is licensed or approved (FDA, tissue establishment registration).
When the responsible center is unclear
For informal product-assignment questions, FDA names the CBER Product Jurisdiction Officer. For a related explanation, read RegAffairs AI's cited answer on what FDA CBER regulates. A formal assignment goes through a Request for Designation to the Office of Combination Products (FDA, CBER product jurisdiction).